Alexion Pharmaceuticals (ALXN) Trading Up 5.1%
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were up 5.1% during trading on Tuesday . The company traded as high as $128.13 and last traded at $127.70. Approximately 1,344,696 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 1,761,062 shares. The stock had previously closed at $121.49.
Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Barclays boosted their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research report on Friday, September 28th. Stifel Nicolaus lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the company from $154.00 to $130.00 in a research report on Tuesday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Finally, ValuEngine lowered shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $160.74.
The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72. The firm has a market cap of $30.98 billion, a price-to-earnings ratio of 23.98, a P/E/G ratio of 1.27 and a beta of 0.79.
Large investors have recently modified their holdings of the business. First Hawaiian Bank purchased a new position in Alexion Pharmaceuticals during the third quarter valued at approximately $102,000. Point72 Asia Hong Kong Ltd lifted its holdings in Alexion Pharmaceuticals by 3,156.7% during the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 947 shares in the last quarter. Advisory Services Network LLC lifted its holdings in Alexion Pharmaceuticals by 145.3% during the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 523 shares in the last quarter. Berson & Corrado Investment Advisors LLC purchased a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $205,000. Finally, Financial Gravity Wealth Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $211,000. 93.06% of the stock is currently owned by institutional investors and hedge funds.
About Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Article: Can individual investors take part in an IPO?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.